In the Press

Filters
Type
Sectors
Geography
Companies

Sign up for our free
equity research notes

Register
1339 Results
Embed
Investment trust insider on EMEA

Investment trust insider on EMEA – James Carthew: In emerging market turmoil, ‘eclectic’ EMEA has surprise appeal China still dominates the MSCI Emerging Markets Index, accounting for 30% of the benchmark at the end of November 2022. Its weak markets, largely a product of its zero-Covid policy, have weighed on the returns of global emerging […]

Investment Trust Insider on Perpetual Income and Growth
Investment trust insider on Chrysalis

Investment trust insider on Chrysalis – James Carthew: How Chrysalis could re-rate after a bad year Chrysalis (CHRY) has been in the news as the board has agreed the new terms of the fund manager’s performance fee which shareholders will need to approve. It still faces the criticism that, unlike most fees in the private […]

Investment Trust Insider on Perpetual Income and Growth
Clearer picture, calmer nerves for renewables?

James Carthew of QuotedData for Investment Week, 5 December 2022: Shifting sentiment has led to a widening of discounts to net asset value across many parts of the investment companies’ industry. One of the more unexpected deratings has occurred within the renewable energy infrastructure sector, despite two thirds of these funds generating double-digit NAV returns […]

Biotech trusts top performance charts in February
Renewable energy infrastructure trusts hold out against extra profits levy

By Val Cipriani, Investors’ Chronicle, November 30 2022: Renewable energy infrastructure trusts are taking a relatively small hit from the electricity generator levy, as its effect on their net asset value (NAV) is offset by high power prices and inflation in the latest round of portfolio updates – but share prices are still recovering quite […]

Biotech trust Trump benefit may be shortlived
Investment trust insider on AT85

Investment trust insider on AT85 – James Carthew: AT85 braves IPO as infrastructure recovers Fundraising in the investment company sector ran into the sand over the summer, culminating with Pantheon Infrastructure (PINT) pulling its planned C-share offer. PINT had a very successful flotation, raking in £400m a little over a year ago versus a target […]

Investment Trust Insider on Perpetual Income and Growth
Investment trust insider on the electricity generator levy

Investment trust insider on the electricity generator levy – James Carthew: Government’s incompetence to renewables windfall tax a crying shame The incredible rise in power prices over the past year was undoubtedly good news for UK-focused renewable energy generators. Not all of the spike in the market price for power was captured by these companies […]

Investment Trust Insider on Capital Gearing Trust
The US trusts on wide discounts relative to their recent history

By Tom Aylott, Reporter, Trustnet, 21 November 2022: Trusts investing in the growth-oriented US market have faced challenging conditions this year as their investment style falls out of favour… On the bright side, declining markets could offer an attractive entry point for investors looking to increase their exposure to the US. Here, Trustnet looks at […]

Trustnet
Deep Dive: ESG lens may boost value opportunities

James Baxter-Derrington, Investment Week, 18 November 2022: Inflation and tightening monetary policy have combined to benefit value investors in the near term, while an ESG lens may provide long-term opportunities in the US and globally. Speaking to Investment Week, Aaron Dunn, co-head of value investing at Eaton Vance, said inflation and tight monetary policy will […]

Biotech trusts top performance charts in February
Trusts’ unlisted headache

By Dave Baxter, Investors’ Chronicle, November 17, 2022: Investment trusts typically demonstrate their strength in a crisis. Closed-ended equity income funds shrugged off the dividend cuts of 2020 thanks to revenue reserves, while trusts’ investment framework means they have encountered none of the liquidity problems demonstrated so clearly by the Neil Woodford scandal. That structure, […]

Biotech trust Trump benefit may be shortlived
Investment trusts hold up as refinancing risks loom

By Dave Baxter, Investors’ Chronicle, November 17, 2022: Is the cure worse than the disease? Some might feel that way about central banks raising interest rates to tackle inflation: a sharp increase in the cost of borrowing has already caused pain in various parts of the UK economy, from a fixed income sell-off to the […]

Biotech trust Trump benefit may be shortlived